SightGlass Vision Spectacles Control Myopia Progression for 6- and 7-Year-Olds, According to New Data Analysis – NCC2022

PALO ALTO, CALIF., June 23, 2022—Analysis of 24-month interim data from the pivotal CYPRESS clinical trial is offering increased hope for controlling myopia progression among young children. Spectacles that use SightGlass Vision^™ Diffusion Optics Technology^™ were shown to significantly reduce both axial length (mean absolute reduction = 0.27 mm) and cycloplegic SER progression (mean absolute reduction = 0.77 D) in six- and seven-year-old children versus the control.*

Two Year Effectiveness of a Novel Myopia Management Spectacle Lens in Young Myopes (Rappon J, Neitz J, Neitz M, Chalberg T) will be presented for the first time at the 2022 Dutch Contact Lens Congress (NCC), which begins next week in Eindhoven, The Netherlands.

The focus on age is of particular interest to eye care professionals and researchers, as myopia progresses fastest in the youngest children.^¹,² Since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health.

“Young myopes can be difficult to manage for many reasons. Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children,” said Andrew Sedgwick, CEO of SightGlass Vision. “Our latest analysis suggests that spectacles enabled with SightGlass Vision^™ Diffusion Optics Technology^™ offer a promising new approach to myopia control for six- and seven-year-olds.”

Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D, with nearly a third of them being six or seven years old. With a mean age of 8.1 years at screening, the entire CYPRESS cohort is younger than children in many other well-known myopia management studies across various interventions. The trial is now in its third year.

Spectacle lenses using patent-protected SightGlass Vision^™ Diffusion Optics Technology^™️ incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.

The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people—half the world’s population—will be myopic by 2050.³ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁴

# # #

About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

Media Contact

Mike McDougall, APR, Fellow PRSA

McDougall Communications for SightGlass Vision

+1-585-434-2150 or mike@mcdougallpr.com

[1] Hyman L, et al. Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial. Archives of Ophthalmology. 2005;123(7):977 987.

[2] Verkicharla PK, Kammari P, Das AV. Myopia progression varies with age and severity of myopia. PLOS ONE. 2020;15(11):e0241759.

[3] Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42

[4] Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363